Oncology Advisory Council
Dr. Shayma M. Kazmi, MD, RPhMD, DO
Dr. Shayma M. Kazmi is a medical oncologist practicing in New Jersey as part of University of Pennsylvania Abramson Cancer Institute. She is also Assistant Professor at Rowan Medical School associated with Virtua Hospital Networks, involved in curricula development for medical training for incoming students and residents. She specializes in the treatment of thoracic malignancies, including lung cancer, head and neck cancer, thyroid cancer, brain cancer as well as breast cancer.
After completing her BS in Pharmacy at Rutgers College of Pharmacy, she pursued her medical degree at Robert Wood Johnson Medical School. She then completed her residency there and embarked on Hematology/Oncology Fellowship with Cancer Institute of New Jersey where she was elected to be Chief Fellow. She worked as a pharmacist throughout most of her medical training.
Prior to her role at Penn Oncology, she served as Medical Director of Thoracic Oncology at Cancer Treatment Centers of America in Philadelphia. She has been primary and secondary investigator in dozens of clinical trials throughout her career. She has presented abstracts and posters at ASCO and ESMO and has had several publications in lung cancer, precision medicine, breast cancer and physician burnout. She has given several invited grand rounds and continues to speak at educational oncological events throughout the country. She has been the Chair of several Best of ASCO programs as well.
She currently serves on the Thoracic Program Leadership Committee at Virtua Hospitals, she is the SITC podcast project lead as part of the Education and Training Committee. She is also an active member of the IASLC Education Committee. She serves as a consultant and subject matter expert in national and international Foundation medicine tumor board discussions. She also volunteers at a local free health clinic. She has served on the board of American Lung Association and participated in several lung cancer screening initiatives.
She is passionate about medical education, precision medicine and medical care access for cancer patients.
Brian Leyland-Jones BSc (1 st Class Hons), MB BS, LRCP, MRCS, ECFMG, PhD, FACP, FRCPC
Dr. Leyland-Jones is a past Chief of Developmental Therapeutics at the National Cancer Institute (NCI) and has served as principal, co-principal, and co-investigator on more than 100 clinical studies. While at the NCI. he coordinated the international development of Paclitaxel, and while at McGill, made numerous contributions to the development of Herceptin, including the design of 0648G (metastatic approval), the design of HERA, the design of NeoSphere and he pioneered the 3-weekly schedule.
He has authored and co-authored more than 246 peer reviewed articles and book contributions, 25 books and book chapters, 427 abstracts and 35 patents. He is the recipient of numerous prestigious awards and honors, including being presented with the 2021 McGill University Lifetime Achievement award as well as being awarded the Cheadle Gold Medal at graduation. He is a recipient of grants from the NCI (P30), NCIC, DOD Breast Cancer Center of Excellence Award and FDA (Orphan). Dr. Leyland-Jones is also a recipient of PMA Clinical Fellow and Faculty Awards and was a 2007 Georgia Research Alliance, Eminent Scholar and a Georgia Cancer Coalition, Distinguished Cancer Scholar.
Dr. Leyland-Jones has served as the director of two major cancer centers, holding positions as the Founding Chair of Oncology and Director of the McGill University Comprehensive Cancer Center (Minda de Gunzberg Chair); Director of the Winship Cancer Centre and Associate Vice President of Health Science at Emory University (first director to achieve NCI designation in 30 years). He was also a Visiting Professor at Stanford University and also served as Vice President of the Molecular and Experimental Genomics Medicine Program at the Avera Cancer Institute.
He holds biochemistry, medical and doctoral degrees from the University of London. Dr. Leyland-Jones completed residency training at London hospitals including St. Mary’s, Hammersmith, Brompton, St. Bartholomew’s and the London Hospital. He completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.
He is a Harvard alumnus (HBS Managing Health Care Delivery, Preparing to be a Corporate Director- Board Governance and PLD35). He has founded or co-founded several companies including Xanthus Pharmaceuticals Ltd (exit to Antisoma), AKESOgen Inc. (exit to Tempus), Viviphi, Parthen and PITO. Dr. Leyland-Jones is an Emeritus Board Member for the WIN Consortium. He currently serves as Chief Medical Officer, Board Member and Treasurer of the National Foundation for Cancer Research (NFCR), Scientific Advisory Board Member for the Asian Foundation for Cancer Research (AFCR) and Vice-Chair of AIM-HI.
Dr. Sanjay Juneja, MD
Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, but better known for social & news media presence as “TheOncDoc”, which boasts over half a million subscribers. He was an active participant for the White House Healthcare Leaders in Social Media Roundtable in 2022 and serves on medical advisory boards for several biotech companies and startups.
Dr. Juneja is the host of an innovative podcast called “Target: Cancer” with distinguished guests discussing the novel advancements and updates in the new world of cancer treatment, and Co-Founder of medfluencers.com which provides access to over 40 million subscribers between their healthcare creators. He has been featured by several media outlets including The Washington Post, WebMD, NPR and PBS, and has guested on dozens of acclaimed podcasts. Dr. Juneja partners regularly on national campaigns and keynote presentations on the role of public-facing cancer education with the Leukemia Lymphoma Society, American Cancer Society, Alliance for Patient Access and the Medical Learning Institute.
Lastly, Dr. Juneja is a Business Report's 40 under 40 recipient and 2023’s People To Watch in his hometown of Baton Rouge, where he practices with his wife and their three rambunctious boys. There, he is passionate about community care inequity and partners regularly with the LA Department of Health and Mayor’s office to optimize healthcare access and outreach.
Dr. Juneja received his medical degree and training at LSU Shreveport and Feist Weiller Cancer Center, where he served as Student Body President of the medical school and residency council, as well as Chief Fellow. Dr. Juneja and his wife both currently practice in Baton Rouge, Louisiana and are parents to three boys.
Dr. Reshma L. Mahtani, MD, DO
Dr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
After completing her master of science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Prior to assuming her role at the Miami Cancer Institute, Dr.Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal and Practice Update (an online medical education platform for physicians). She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series. She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients’ access to healthcare and community collaborations for education and advocacy.
